- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
- Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
- Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
- Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
- Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
More ▼
Key statistics
On Tuesday, Phathom Pharmaceuticals Inc (PHAT:NSQ) closed at 9.06, 49.38% above the 52 week low of 6.07 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.01 |
---|---|
High | 9.29 |
Low | 8.92 |
Bid | 8.93 |
Offer | 10.28 |
Previous close | 9.01 |
Average volume | 714.43k |
---|---|
Shares outstanding | 58.52m |
Free float | 52.95m |
P/E (TTM) | -- |
Market cap | 527.30m USD |
EPS (TTM) | -3.89 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼